SCHEMBL4500488

SCHEMBL4500488

O=C1CCCCN1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PKM P14618 1/20 0.44
ADORA3 P0DMS8 1/20 0.39
HSD11B1 P28845 6/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
HSD17B1 P14061 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
EPHX2 P34913 3/20 0.33
S1PR2 O95136 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
BPTF Q12830 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4518124 0.98 MEN1 (0.42) MEN1KMT2APKMADORA3HSD11B1
SCHEMBL206785 0.94 MEN1 (0.49) MEN1KMT2APKMADORA3HSD11B1
SCHEMBL1896319 0.86 MEN1 (0.40) MEN1KMT2APKMADORA3HSD11B1
SCHEMBL19271807 0.77 ALDH1A1 (0.39) MEN1KMT2APKM
SCHEMBL9068591 0.74 MEN1 (0.36) MEN1KMT2APKMADORA3HSD11B1
SCHEMBL23920667 0.74 ALDH1A1 (0.45) MEN1KMT2APKML3MBTL1
SCHEMBL4511612 0.73 KMT2A (0.44) MEN1KMT2APKMHSD11B1EPHX2
SCHEMBL1397765 0.70 MEN1 (0.33) MEN1KMT2APKM
SCHEMBL4501285 0.69 ALDH1A1 (0.38) MEN1KMT2AL3MBTL1POLBLMNA
SCHEMBL23538864 0.67 BRD4 (0.39) MEN1KMT2APKMTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3237903-B1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RES & ENG CO (US) 2020-02-26 EP claimed
EP-3237903-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 EP claimed
EP-3237904-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 EP claimed
WO-2016106211-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 WO claimed
US-20160187315-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 US claimed
US-20160187314-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 US claimed
WO-2016106214-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 WO claimed
EP-3237903-B1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RES & ENG CO (US) 2020-02-26 EP disclosed
EP-3237904-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 EP disclosed
EP-3237903-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 EP disclosed
US-20160187315-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 US disclosed
WO-2016106214-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 WO disclosed
WO-2016106211-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 WO disclosed
US-20160187314-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
US-6887646-B1 Chemical amplification resist composition MITSUBISHI RAYON CO., LTD. (JP) 2005-05-03 US disclosed
EP-1209525-A1 CHEMICAL AMPLIFICATION RESIST COMPOSITION Mitsubishi Rayon Co., Ltd. (JP) 2002-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 MEN1 1254/4885KMT2A 2379/4885PKM 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.